Search
# Popular search #
中文站
# Popular search #
山东
甘李药业股份有限公司的全资子公司，于2019年9月在山东临沂成立。
主营业务：主要负责药品及医疗器械的生产等工作。
上海
甘李药业股份有限公司的全资子公司，于2020年在上海成立。
主营业务：国际商业合作（BD）
香港
甘李药业股份有限公司的全资子公司，于2020年在中国香港成立。
主营业务：国际商业合作（BD）
美国
甘李药业股份有限公司的全资子公司，于2014年在美国新泽西州成立。
主营业务：主要负责海外临床、注册及业务拓展等工作。
美国
甘李药业股份有限公司的全资子公司，于2020年在美国新泽西州成立。
主营业务：欧美业务、生产及销售。
美国
甘李药业股份有限公司的全资子公司，于2020年在美国新泽西州成立。
主营业务：欧美业务、生产及销售。
北京
1998年成立，位于北京通州经济开发区，拥有约20万平方米的产业园。
北京
甘李药业股份有限公司的全资子公司，于2007年在北京成立。
主营业务：糖尿病治疗配套医疗器械的产品研发设计、新技术开发。
江苏
甘李药业股份有限公司的全资子公司，于2015年在江苏泰州成立。 主营业务：化学药品生产基地。建设有多肽合成原料药车间、固体口服制剂车间（片剂）和化学原料药合成车间以及与之配套的办公、质检、仓储、环保等辅助设施。
江苏
北京甘甘科技有限公司的全资子公司，于2017年在江苏泰州成立。 主营业务：着重于将相关研发成果转换为合规的生产经营活动。主要产品有笔式胰岛素注射器（秀霖笔®）、血糖仪、血糖试纸、笔式注射器（预装式）、一次性胰岛素笔用针头（秀霖针®）等。
德国
甘李药业股份有限公司的全资子公司，于2021年在德国成立。
主营业务：欧洲业务、临床及销售等。
Founded in 1998, the company is located in Beijing, with an industrial base of approximately about 200,000 square meters.
A wholly-owned subsidiary of the Company, established in Linyi, Shandong Province in China, 2019.
Main Business: the production of medicinal products and medical devices.
A wholly-owned subsidiary of the Company, which was established in Beijing, 2007.
Main Business: R&D of medical devices for diabetes treatment
A wholly-owned subsidiary of Gangan Technology, established in Taizhou, Jiangsu Province in China, 2017.
Main Business: Converting relevant R&D results into compliant production and operation activities. The main products include pen-type insulin syringes (GanleePen), blood glucose meters, blood glucose test strips, pre-filled pens, disposable insulin pen needles (GanleeFine®), etc.
A wholly-owned subsidiary of the Company, established in Taizhou, Jiangsu Province in China, 2015
Main Business: Chemical production base, which has a polypeptide synthesis raw material medicine production line, a solid oral preparation production line (tablet) and a chemical raw material medicine synthesis production line, as well as supporting facilities such as office, quality inspection, storage, and environmental protection.
A wholly-owned subsidiary of the Company, established in Hong Kong in China, 2020.
Main Business: International Business Development
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2014.
Main Business: overseas clinical, registration, business development.
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2020.
Main Business: International Business Development
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2020.
Main Business: US & European business, production, and sales.
A wholly-owned subsidiary established by the Company established in Germany in 2021.
Main Business: European business, clinical affairs, and sales.
Founded in 1998, the company is located in Beijing, with an industrial base of approximately about 200,000 square meters.
A wholly-owned subsidiary of the Company, established in Linyi, Shandong Province in China, 2019.
Main Business: the production of medicinal products and medical devices.
A wholly-owned subsidiary of the Company, which was established in Beijing, 2007.
Main Business: R&D of medical devices for diabetes treatment
A wholly-owned subsidiary of Gangan Technology, established in Taizhou, Jiangsu Province in China, 2017.
Main Business: Converting relevant R&D results into compliant production and operation activities. The main products include pen-type insulin syringes (GanleePen), blood glucose meters, blood glucose test strips, pre-filled pens, disposable insulin pen needles (GanleeFine®), etc.
A wholly-owned subsidiary of the Company, established in Taizhou, Jiangsu Province in China, 2015
Main Business: Chemical production base, which has a polypeptide synthesis raw material medicine production line, a solid oral preparation production line (tablet) and a chemical raw material medicine synthesis production line, as well as supporting facilities such as office, quality inspection, storage, and environmental protection.
A wholly-owned subsidiary of the Company, established in Hong Kong in China, 2020.
Main Business: International Business Development
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2014.
Main Business: overseas clinical, registration, business development.
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2020.
Main Business: International Business Development
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2020.
Main Business: US & European business, production, and sales.
A wholly-owned subsidiary established by the Company established in Germany in 2021.
Main Business: European business, clinical affairs, and sales.
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.